Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance and Otsuka Pharmaceutical to Collaborate on PGx Study of Drug Response

NEW YORK, Sept. 21 (GenomeWeb News) - Genaissance Pharmaceuticals will conduct genotyping studies for Otsuka Pharmaceutical of Japan, the companies said today.

 

Under the research collaboration, New Haven, Conn.-based Genaissance will apply its HAP technology to identify genetic markers related to drug response. Both companies will own intellectual property resulting from the collaboration and will be eligible for royalties on revenues from diagnostic products that come out of the project.

 

The Otsuka Pharmaeutical Group, based in Tokyo, comprises 73 companies with 23,000 employees and has $4.4 billion in annual revenues.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more